Kimberly R Lockett

Array ( [id] => 6957850 [patent_doc_number] => 20050214220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-09-29 [patent_title] => 'Tumor model' [patent_app_type] => utility [patent_app_number] => 11/089545 [patent_app_country] => US [patent_app_date] => 2005-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10364 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0214/20050214220.pdf [firstpage_image] =>[orig_patent_app_number] => 11089545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7068962 [patent_doc_number] => 20050244345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-11-03 [patent_title] => 'Method for preventing mineralization in the periodontal ligament (PDL)' [patent_app_type] => utility [patent_app_number] => 11/081566 [patent_app_country] => US [patent_app_date] => 2005-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5421 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0244/20050244345.pdf [firstpage_image] =>[orig_patent_app_number] => 11081566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7178873 [patent_doc_number] => 20050204410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-09-15 [patent_title] => 'SIRT6 transgenic non-human animals and assay methods' [patent_app_type] => utility [patent_app_number] => 11/078113 [patent_app_country] => US [patent_app_date] => 2005-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6556 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0204/20050204410.pdf [firstpage_image] =>[orig_patent_app_number] => 11078113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7107894 [patent_doc_number] => 20050108780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-05-19 [patent_title] => 'Intracellular antibodies for a retrovirus protein' [patent_app_type] => utility [patent_app_number] => 10/894194 [patent_app_country] => US [patent_app_date] => 2004-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15180 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0108/20050108780.pdf [firstpage_image] =>[orig_patent_app_number] => 10894194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 725297 [patent_doc_number] => 07045678 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-05-16 [patent_title] => 'Transgenic mouse for screening therapeutic agents for brain tumors' [patent_app_type] => utility [patent_app_number] => 10/829491 [patent_app_country] => US [patent_app_date] => 2004-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9598 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/045/07045678.pdf [firstpage_image] =>[orig_patent_app_number] => 10829491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7436188 [patent_doc_number] => 20040185060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-09-23 [patent_title] => 'Immunological enhancement agent comprising N-terminal peptide of p43 as an effective component' [patent_app_type] => new [patent_app_number] => 10/823730 [patent_app_country] => US [patent_app_date] => 2004-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3596 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0185/20040185060.pdf [firstpage_image] =>[orig_patent_app_number] => 10823730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7301032 [patent_doc_number] => 20040216178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-10-28 [patent_title] => 'Regulation of mdm2 function' [patent_app_type] => new [patent_app_number] => 10/793389 [patent_app_country] => US [patent_app_date] => 2004-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 9245 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0216/20040216178.pdf [firstpage_image] =>[orig_patent_app_number] => 10793389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7216369 [patent_doc_number] => 20050044578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-02-24 [patent_title] => 'Rat highly sensitive to carcinogen' [patent_app_type] => utility [patent_app_number] => 10/784633 [patent_app_country] => US [patent_app_date] => 2004-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3475 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0044/20050044578.pdf [firstpage_image] =>[orig_patent_app_number] => 10784633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7335174 [patent_doc_number] => 20040132179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-07-08 [patent_title] => 'Treatment of t cell disorders' [patent_app_type] => new [patent_app_number] => 10/399213 [patent_app_country] => US [patent_app_date] => 2004-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 15436 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0132/20040132179.pdf [firstpage_image] =>[orig_patent_app_number] => 10399213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7407304 [patent_doc_number] => 20040106093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-06-03 [patent_title] => 'Myb-transformed blood cells and their use for active ingredient screening' [patent_app_type] => new [patent_app_number] => 10/471343 [patent_app_country] => US [patent_app_date] => 2004-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3105 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0106/20040106093.pdf [firstpage_image] =>[orig_patent_app_number] => 10471343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7445275 [patent_doc_number] => 20040210953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-10-21 [patent_title] => 'Lysozyme transgenic ungulates' [patent_app_type] => new [patent_app_number] => 10/753587 [patent_app_country] => US [patent_app_date] => 2004-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12808 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0210/20040210953.pdf [firstpage_image] =>[orig_patent_app_number] => 10753587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7327155 [patent_doc_number] => 20040253303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-12-16 [patent_title] => 'Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma' [patent_app_type] => new [patent_app_number] => 10/730034 [patent_app_country] => US [patent_app_date] => 2003-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7821 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0253/20040253303.pdf [firstpage_image] =>[orig_patent_app_number] => 10730034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6938544 [patent_doc_number] => 20050112107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-05-26 [patent_title] => 'Method for preventing mineralization in the periodontal ligament (PDL)' [patent_app_type] => utility [patent_app_number] => 10/717708 [patent_app_country] => US [patent_app_date] => 2003-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5419 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0112/20050112107.pdf [firstpage_image] =>[orig_patent_app_number] => 10717708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7343839 [patent_doc_number] => 20040191901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-09-30 [patent_title] => 'Insulin producing cells derived from human embryonic stem cells' [patent_app_type] => new [patent_app_number] => 10/714348 [patent_app_country] => US [patent_app_date] => 2003-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11460 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0191/20040191901.pdf [firstpage_image] =>[orig_patent_app_number] => 10714348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7294788 [patent_doc_number] => 20040213739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-10-28 [patent_title] => 'Screening markers and methods for neurodegenerative disorders' [patent_app_type] => new [patent_app_number] => 10/685992 [patent_app_country] => US [patent_app_date] => 2003-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7333 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 3 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0213/20040213739.pdf [firstpage_image] =>[orig_patent_app_number] => 10685992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7477431 [patent_doc_number] => 20040123335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-06-24 [patent_title] => 'Prevention of primary Sjogren\'s Syndrome by ICA69 deficiency' [patent_app_type] => new [patent_app_number] => 10/679081 [patent_app_country] => US [patent_app_date] => 2003-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7931 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0123/20040123335.pdf [firstpage_image] =>[orig_patent_app_number] => 10679081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 729408 [patent_doc_number] => 07041869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-05-09 [patent_title] => 'Transgenic luciferase mouse' [patent_app_type] => utility [patent_app_number] => 10/679231 [patent_app_country] => US [patent_app_date] => 2003-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 6813 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/041/07041869.pdf [firstpage_image] =>[orig_patent_app_number] => 10679231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7310457 [patent_doc_number] => 20040142890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-07-22 [patent_title] => 'Methods and compositions for treating prostate cancer using DNA vaccines' [patent_app_type] => new [patent_app_number] => 10/669474 [patent_app_country] => US [patent_app_date] => 2003-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 13397 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20040142890.pdf [firstpage_image] =>[orig_patent_app_number] => 10669474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7150936 [patent_doc_number] => 20040171565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-09-02 [patent_title] => 'DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity' [patent_app_type] => new [patent_app_number] => 10/632095 [patent_app_country] => US [patent_app_date] => 2003-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12658 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0171/20040171565.pdf [firstpage_image] =>[orig_patent_app_number] => 10632095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7425232 [patent_doc_number] => 20040161408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-08-19 [patent_title] => 'Uses of circadian gene mPer2' [patent_app_type] => new [patent_app_number] => 10/627207 [patent_app_country] => US [patent_app_date] => 2003-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 9402 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0161/20040161408.pdf [firstpage_image] =>[orig_patent_app_number] => 10627207 [rel_patent_id] =>[rel_patent_doc_number] =>)